Use of liposomal anthracyclines in Kaposi's sarcoma
SE Krown, DW Northfelt, D Osoba, JS Stewart - Seminars in oncology, 2004 - Elsevier
Conventional chemotherapy regimens for the treatment of advanced Kaposi’s sarcoma (KS)
show limited efficacy and considerable toxicity. Liposomal anthracyclines with potential …
show limited efficacy and considerable toxicity. Liposomal anthracyclines with potential …
Trastuzumab-induced cardiotoxicity: heart failure at the crossroads
PP Sengupta, DW Northfelt, F Gentile… - Mayo Clinic …, 2008 - Elsevier
Trastuzumab, a drug targeting human epidermal growth factor receptor 2, improves survival
rate in women with metastatic breast cancer. Symptomatic heart failure, a serious adverse …
rate in women with metastatic breast cancer. Symptomatic heart failure, a serious adverse …
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III …
DW Northfelt, BJ Dezube, JA Thommes… - Journal of clinical …, 1998 - ascopubs.org
PURPOSE Kaposi's sarcoma (KS), the most common neoplasm in patients with AIDS, is a
significant clinical problem for which current therapies are frequently unsatisfactory. We …
significant clinical problem for which current therapies are frequently unsatisfactory. We …
The future of contrast-enhanced mammography
…, R Lorans, BA Pockaj, DW Northfelt… - American Journal of …, 2018 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to discuss facilitators of and barriers to future
implementation of contrast-enhanced mammography (CEM) in the United States. CONCLUSION. …
implementation of contrast-enhanced mammography (CEM) in the United States. CONCLUSION. …
[HTML][HTML] Adaptive randomization of veliparib–carboplatin treatment in breast cancer
…, BB Haley, R Nanda, DW Northfelt… - … England Journal of …, 2016 - Mass Medical Soc
Background The genetic and clinical heterogeneity of breast cancer makes the identification
of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively …
of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively …
[HTML][HTML] Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
…, RK Murthy, R Nanda, DW Northfelt… - The Lancet …, 2022 - thelancet.com
Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
Doxorubicin encapsulated in liposomes containing surface‐bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS‐related …
DW Northfelt, FJ Martin, P Working… - The Journal of …, 1996 - Wiley Online Library
A study of the plasma pharmacokinetics, tumor localization, and safety of a single dose of
doxorubicin encapsulated in liposomes containing surface‐bound polyethylene glycol (PEG‐…
doxorubicin encapsulated in liposomes containing surface‐bound polyethylene glycol (PEG‐…
[HTML][HTML] Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
…, TP Cooley, B Herndier, DW Northfelt… - … England Journal of …, 1997 - Mass Medical Soc
Background Reduced doses of cytotoxic chemotherapy or standard-dose therapy plus a
myeloid colony-stimulating factor decreases hematologic toxicity and its complications in …
myeloid colony-stimulating factor decreases hematologic toxicity and its complications in …
[HTML][HTML] Adaptive randomization of neratinib in early breast cancer
…, KK Edmiston, AD Elias, DW Northfelt… - … England Journal of …, 2016 - Mass Medical Soc
Background The heterogeneity of breast cancer makes identifying effective therapies challenging.
The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-…
The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-…
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer
MD Pegram, T Pienkowski, DW Northfelt… - Journal of the …, 2004 - academic.oup.com
Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of
both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. The University of …
both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. The University of …